OptimizeRx Co. (NASDAQ:OPRX) – Investment analysts at B. Riley dropped their FY2019 earnings per share estimates for OptimizeRx in a research report issued to clients and investors on Monday, December 30th. B. Riley analyst A. D’silva now forecasts that the company will post earnings per share of ($0.12) for the year, down from their prior forecast of ($0.10). B. Riley has a “Buy” rating and a $20.00 price objective on the stock. B. Riley also issued estimates for OptimizeRx’s Q4 2019 earnings at ($0.08) EPS, Q1 2020 earnings at ($0.08) EPS, Q2 2020 earnings at $0.01 EPS, Q3 2020 earnings at $0.01 EPS, Q4 2020 earnings at $0.02 EPS, FY2020 earnings at ($0.03) EPS and FY2021 earnings at $0.21 EPS.
OptimizeRx (NASDAQ:OPRX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.15). OptimizeRx had a negative return on equity of 3.68% and a negative net margin of 5.32%. The firm had revenue of $5.00 million for the quarter, compared to the consensus estimate of $7.21 million.
OPRX has been the subject of a number of other reports. TheStreet lowered shares of OptimizeRx from a “c” rating to a “d+” rating in a research report on Wednesday, November 20th. Zacks Investment Research downgraded OptimizeRx from a “hold” rating to a “sell” rating in a research report on Tuesday, November 5th. Finally, ValuEngine raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $18.00.
Shares of NASDAQ:OPRX opened at $10.27 on Wednesday. The firm has a fifty day moving average price of $10.04 and a two-hundred day moving average price of $13.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.00 and a quick ratio of 7.00. OptimizeRx has a one year low of $8.63 and a one year high of $17.24. The company has a market cap of $145.53 million, a price-to-earnings ratio of 205.40 and a beta of 0.36.
Several institutional investors and hedge funds have recently bought and sold shares of OPRX. Barclays PLC increased its position in shares of OptimizeRx by 34.7% during the 3rd quarter. Barclays PLC now owns 10,403 shares of the company’s stock valued at $151,000 after purchasing an additional 2,678 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of OptimizeRx by 9.5% during the 2nd quarter. Wells Fargo & Company MN now owns 13,562 shares of the company’s stock valued at $219,000 after buying an additional 1,180 shares in the last quarter. California State Teachers Retirement System lifted its position in OptimizeRx by 16.5% in the 3rd quarter. California State Teachers Retirement System now owns 21,500 shares of the company’s stock worth $311,000 after buying an additional 3,049 shares during the last quarter. Squarepoint Ops LLC lifted its position in OptimizeRx by 25.0% in the 3rd quarter. Squarepoint Ops LLC now owns 27,000 shares of the company’s stock worth $391,000 after buying an additional 5,400 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new stake in OptimizeRx in the second quarter worth approximately $454,000. Hedge funds and other institutional investors own 60.64% of the company’s stock.
In related news, CEO William J. Febbo acquired 5,000 shares of the stock in a transaction dated Wednesday, November 6th. The shares were purchased at an average price of $10.38 per share, for a total transaction of $51,900.00. 8.40% of the stock is owned by corporate insiders.
About OptimizeRx
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company’s cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
